References

Abramowski D, Rigo M, Duc D, et al (1995) Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 34:1635-1645.

Adam K, Oswald I (1989) Effects of repeated ritanserin on middle-aged poor sleepers. Psychopharmacology 99:219-221.

Adrian J (2008) Sleep and waking in mutant mice that do not express various proteins involved in serotonergic neurotransmission such as the serotonergic transporter, monoamine oxidase A, and 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C and 5-HT7 receptors. In: Monti JM, Pandi-Perumal SR, Jacobs BL, et al, eds. Serotonin and Sleep: Molecular, Functional and Clinical Aspects. Basel: Birkhäuser, pp. 457-475

Amici R, Sanford LD, Kearney K, et al (2004) A serotonergic (5-HT2) receptor mechanism in the laterodorsal tegmental nucleus participates in regulating the pattern of rapid-eye-movement sleep occurrence in the rat. Brain Res 996:9-18.

Amin AH, Crawford TBB, Gaddum JH (1954) The distribution of substance P and 5-hydroxytryptamine in the central nervous system of the dog. J Physiol 125:596-618.

Boutrel B, Franc B, Hen R, et al (1999) Key role of 5-HT1B receptors in the regulation of paradoxical sleep as evidenced in 5-HT1B knock-out mice. J Neurosci 19:3204-3212.

Boutrel B, Monaca C, Hen R, et al (2002) Involvement of 5-HT1A receptors in homeostasis and stress-induced adaptive regulations of paradoxical sleep: studies in 5-HT1A knock-out mice. J Neurosci 22:4686-4692.

Chiang C, Aston-Jones G (1993) A 5-hydroxytryptamine-2 agonist augments gamma-aminobu-tyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience 54:409-420.

Clemett DA, Punhani T, Duxon MS, et al (2000) Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 39:123-132.

Coenen AML, Ates N, Skarsfeldt T, et al (1995) Effects of sertindole on sleep-wake states, electroencephalogram, behavioral patterns and epileptic activity in rats. Pharmacol Biochem Behav 51:353-357.

Cohrs S, Rodenbeck A, Guan Z, et al (2004) Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology 174:421-429.

Cohrs S, Meier A, Neumann A-C, et al (2005) Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized controlled crossover trial of 12 healthy male subjects. J Clin Psychiatry 66:989-996.

Cornea-Hebert V, Riad M, Wu C, et al (1999) Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J Comp Neurol 409:187-209.

da Roza Davis JM, Sharpley AL, Cowen PJ (1992) Slow wave sleep and 5-HT2 receptor sensitivity in generalised anxiety disorder. Psychopharmacology 108:387-389.

de Almeida J, Mengod G (2007) Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT(2A) receptors in human and monkey prefrontal cortex. J Neurochem 103:475-486.

Di Matteo V, Di Giovanni G, Di Mascio M, et al (2000) Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin2C receptors. Brain Res 865:85-90.

Dijk DJ, Beersma DGM, Daan S, et al (1989) Effects of seganserin, a 5-HT2 antagonist, and temazepam on human sleep stages and EEG power spectra. Eur J Pharmacol 171:207-218.

Done CJ, Sharp T (1994) Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology 33:411-421.

Dugovic C, Wauquier A (1987) 5-HT2 receptors could be primarily involved in the regulation of slow wave sleep in the rat. Eur J Pharmacol 137:145-146.

Dugovic C, Wauquier A, Leysen JE, et al (1989) Functional role of 5-HT2 receptors in the regulation of sleep and wakefulness in the rat. Psychopharmacology 97:436-442.

Dursun SM, Patel JKM, Burke JG, et al (1999) Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: a pilot study. J Psychiatry Neurosci 24:333-337.

Duxon MS, Flanigan TP, Reavley AC, et al (1997) Evidence for expression of the 5-hydroxytryptam-ine-2B receptor protein in the rat central nervous system. Neuroscience 76:323-329.

Eriksson KS, Stevens DR, Haas HL (2001) Serotonin excites tuberomammillary neurons by activation of Na(+)/Ca(2+)-exchange. Neuropharmacology 40:345-351.

Fay R, Kubin L (2000) Pontomedullary distribution of 5-HT2A receptor-like protein in the rat. J Comp Neurol 418:323-345.

Fink KB, Göthert M (2007) 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 59:360-417.

Ford B, Holmes CJ, Mainville L, et al (1995) GABAergic neurons in the rat pontomesencephalic tegmentum: codistribution with cholinergic and other tegmental neurons projecting to the posterior lateral hypothalamus. J Comp Neurol 363:177-196.

Frank MG, Stryker MP, Tecott LH (2002) Sleep and sleep homeostasis in mice lacking the 5-HT2C receptor. Neuropsychopharmacology 27:869-873.

Garratt JC, Kidd EJ, Wright IK, et al (1991) Inhibition of 5-hydroxytryptamine neuronal activity by the 5-HT agonist DOI. Eur J Pharmacol 199:349-355.

Haffmans PMJ, Oolders JM, Hoencamp E, et al (2001) The effect of risperidone versus haloperi-dol on sleep patterns of schizophrenic patients: results of a double-blind, randomised pilot trial. Eur Neuropsychopharm 11 (suppl 3):S260.

Hannon J, Hoyer D (2008) Molecular biology of 5-HT receptors. In: Monti JM, Pandi-Perumal SR, Jacobs BL, et al., eds. Serotonin and Sleep: Molecular, Functional and Clinical Aspects. Basel: Birkhäuser, pp 155-182.

Hedlund PB, Huitron-Resendiz S, Henriksen SJ, et al (2005) 5-HT7 receptor inhibition and inac-tivation induced antidepressantlike behavior and sleep pattern. Biol Psychiatry 58:831-837.

Heller-Brown J, Taylor P (1996) Muscarinic receptor agonists and antagonists. In: Hardman JG, Limbird LE, eds. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, pp. 141-160.

Hinze-Selch D, Mullington J, Orth A, et al (1997) Effects of clozapine on sleep: a longitudinal study. Biol Psychiatry 42:260-266.

Horacek J (2000) Novel antipsychotics and extrapyramidal side effects. Theory and reality. Pharmacopsychiatry 33 (suppl):34-42.

Idzikowski C, Mills FJ, Glennard R (1986) 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Res 378:164-168.

Idzikowski C, Cowen PJ, Nutt D, et al (1987) The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan. Psychopharmacology 93:416-420.

Idzikowski C, Mills FJ, James RJ (1991) A dose-response study examining the effects of ritanserin on human slow wave sleep. Br J Clin Pharm 31:193-196.

Jacobs BL, Azmitia EC (1992) Structure and function of the brain serotonin system. Physiol Rev 72:165-229.

Jacobs BL, Fornal CA (1999) Activity of serotonergic neurons in behaving animals. Neuropsychopharmacology 21 (suppl 2):9S-15S.

Jäkälä P, Sirvio J, Koivisto E, et al (1995) Modulation of rat neocortical high-voltage spindle activity by 5-HT1/5-HT2 receptor subtype specific drugs. Eur J Pharmacol 82:39-55.

Jones FJ (2003) Arousal systems. Frontiers Biosci 8:438-451.

Kamali F, Stansfield SC, Ashton CH, et al (1992) Absence of withdrawal effects of ritanserin following chronic dosing in healthy volunteers. Psychopharmacology 108:213-217.

Kirov R, Moyanova S (1998) Age-dependent effect of ketanserin on the sleep-waking phases in rats. Int J Neurosci 93:257-264.

Kirov R, Moyanova S (1998) Age-related effect of ritanserin on the sleep-waking phases in rats. Int J Neurosci 93:265-278.

Kitka T, Bagdy G (2008) Effect of 5-HT2A(2B(2C receptor agonists and antagonists on sleep and waking in laboratory animals and humans. In: Monti JM, Pandi-Perumal SR, Jacobs BL, et al, eds. Serotonin and Sleep: Molecular, Functional and Clinical Aspects. Basel: Birkhäuser, pp. 387-414

Landolt HP, Viola M, Burgess HJ, et al (1999) Serotonin-2 receptors and human sleep: Effect of a selective antagonist on EEG power spectra. Neuropsychopharmacology 21:455-466.

Lee JH, Woo JI, Meltzer HY (2001) Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia. Psychiatry Res 103:157-166.

Leysen JE (2004) 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord 3:11-26.

Maixner S, Tandon R, Eiser A, et al (1998) Effects of antipsychotic treatment on polysomnography measures in schizophrenia: a replication and extension. Am Psychiatry 155: 1600-1602.

Martin JR, Bos M, Jenck F, et al (1998) 5-HT2C receptor agonists: Pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913-924.

Mengod G, Nguyen H, Le H, et al (1990) The distribution and cellular localization of the serotonin 1C receptor in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. Neuroscience 35:577-591.

Monti JM (1987) Disturbances of sleep and wakefulness associated with the use of antihyperten-sive agents. Life Sci 41: 1979-1988.

Monti JM, Jantos H (2004) Effects of the 5-HT1A receptor ligands flesinoxan and WAY 100635 given systemically or microinjected into the laterodorsal tegmental nucleus on REM sleep in the rat. Behav Brain Res 151:159-166.

Monti JM, Jantos H (2006a) Effects of the serotonin 5-HT2A(2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat. Eur J Pharmacol 553:163-170.

Monti JM, Jantos H (2006b) Effects of activation and blockade of 5-HT2A(2C receptors in the dorsal raphe nucleus on sleep and waking in the rat. Prog Neuropsychopharmacol Biol Psychiatry 30:1189-1195.

Monti JM, Jantos H (2008) Mechanisms involved in the inhibition of REM sleep by serotonin. In: Monti JM, Pandi-Perumal SR, Jacobs BL, et al, eds. Serotonin and Sleep: Molecular, Functional and Clinical Aspects. Basel: Birkhäuser, pp. 371-385

Monti JM, Monti D (2000a) Role of dorsal raphe nucleus serotonin 5-HT1A receptor in the regulation of REM sleep. Life Sci 66:1999-2012.

Monti JM, Monti D (2000b) Histamine H1 receptor antagonists in the treatment of insomnia. Is there a rational basis for use? CNS Drugs 13:87-96.

Monti JM, Monti D (2004) Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev 8:133-148.

Monti JM, Orellana C, Boussard M, et al (1990) 5-HT receptor agonists 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and 8-OH-DPAT increase wakefulness in the rat. Biogen Amines 7:145-151.

Monti JM, Alterwain P, Estevez F, et al (1993) The effects of ritanserin on mood and sleep in abstinent alcoholic patients. Sleep 16:647-654.

Monti JM, Monti D, Jantos H, et al (1995) Effects of selective activation of the 5-HT1B receptor with CP-94,253 on sleep and wakefulness in the rat. Neuropharmacology 34:1647-1651.

Monti JM, Jantos H, Monti D (2002) Increased REM sleep after intra-dorsal raphe nucleus injection of flesinoxan or 8-OHDPAT: prevention with WAY 100635. Eur Neuropsychopharmacol 12:47-55.

Monti JM, Jantos H, Monti D (2008a) Serotonin and sleep-wake regulation. In: Monti JM, Pandi-Perumal SR, Sinton CM Eds., Neurochemistry of Sleep and Wakefulness. Cambridge: Cambridge University Press, pp. 244-279.

Monti JM, Leopoldo M, Jantos H (2008b) The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat. Behav Brain Res 191:184-189.

Monti JM, Jantos H, Lagos P (2010) Activation of serotonin 5-HT1B receptor in the dorsal raphe nucleus affects REM sleep in the rat. Behav Brain Res 206:8-16.

Muller MJ, Rossbach W, Mann K, et al (2004) Subchronic effects of olanzapine on sleep EEG in schizophrenic patients with predominantly negative symptoms. Pharmacopsychiatry 37:157-162.

Muraki Y, Yamanaka A, Tsujino N, et al (2004) Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. J Neurosci 24:7159-7166.

Muramatsu M, Chaki S, Usuki-Ito C, et al (1990) Attenuation of serotonin-induced suppression of [3H]acetylcholine release from rat cerebral cortex by minaprine: possible involvement of the serotonin-2 receptor and K+ channel. Neurochem Int 16:301-307.

Nair SG, Gudelsky GA (2004) Activation of 5-HT2 receptors enhances the release of acetylcholine in the prefrontal cortex and hippocampus of the rat. Synapse 53:202-207.

Nichols DE, Nichols CD (2008) Serotonin receptors. Chem Rev 108:1614-1641.

Nofzinger EA, van Kammen DP, Gilbertson MW, et al (1993) Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic free. Biol Psychiatry 33:829-835.

Pace-Schott EF, Hobson J (2002) Basic mechanisms of sleep: New evidence on the neuroanatomy and neuromodulation of the NREM-REM cycle. In: Charney D, Nemeroff C, eds. Neuropsychopharmacology - The Fifth Generation of Progress. Philadelphia: Lippincott Williams & Wilkins, pp. 1859-1877.

Paiva T, Arriaga F, Wauquier A, et al (1988) Effects of ritanserin on sleep disturbances in dysthymic patients. Psychopharmacology 96:395-399.

Paxinos G, Watson C (2005) The Rat in Stereotaxic Coordinates - The New Coronal Set, 5th edn. Sydney: Academic.

Pazos A, Cortés R, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346:231-249.

Ponzoni A, Monti JM, Jantos H (1993) The effects of selective activation of the 5-HT3 receptor with m-chlorophenylbiguanide on sleep and wakefulness in the rat. Eur J Pharmacol 249:259-264.

Popa D, Lena C, Fabre V, et al (2005) Contribution of 5-HT2 receptor subtypes to sleep-wakeful-ness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors. J Neurosci 25:11231-11238.

Portas CM, Bjorvatn B, Ursin R (2000) Serotonin and the sleep/wake cycle: special emphasis on microdialysis studies. Prog Neurobiol 60:13-35.

Reynolds GF (2004) Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 18:340-345.

Ruiz-Primo E, Haro R, Valencia M (1989) Polysomnographic effects of ritanserin in insomniacs: a crossed double-blind controlled study. Sleep Res 18:72.

Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, et al (1999) Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 46:141-143.

Schmidt CJ, Fadayel GM (1995) The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 273:273-279.

Sharpley AL, Solomon RA, Fernando AI, et al (1990) Dose-related effects of selective 5-HT2 receptor antagonists on slow wave sleep in humans. Psychopharmacology 101:568-569.

Sharpley AL, Elliott JM, Attenburrow MJ, et al (1994) Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacology 33:467-471.

Sharpley AL, Vassallo CM, Cowen PJ (2000) Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo. Biol Psychiatry 47:468-470.

Sharpley AL, Bhagwagar Z, Hafizi S, et al (2003) Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. J Clin Psychiatry 64:192-196.

Silhol S, Glin L, Gottesmann C (1991) Study of the 5-HT2 antagonist ritanserin on sleep-waking cycle in the rat. Physiol Behav 41:241-243.

Smith MI, Piper DC, Duxon MS, et al (2002) Effect of SB-243213, a selective 5-HT2C receptor antagonist, on the rat sleep profile: a comparison to paroxetine. Pharmacol Biochem Behav 71:599-605.

Staner L, Kempenaers C, Simonnet MP, et al (1992) 5-HT2 receptor antagonism and slow-wave sleep in major depression. Acta Psychiatr Scand 86:133-137.

Taylor SF, Tandon R, Shipley JE, et al (1991) Effect of neuroleptic treatment on polysomnography measures in schizophrenia. Biol Psychiatry 30:904-912.

Tortella FC, Echevarría E, Pastel RH, et al (1989) Suppressant effects of selective 5-HT2 antagonists on rapid eye movement sleep in rats. Brain Res 485:294-300.

Touyz SW, Saayman GS, Zabow T (1978) A psychophysiological investigation of the long-term effects of clozapine upon sleep patterns of normal young adults. Psychopharmacology 56:69-73.

Trulson ME, Jacobs BL (1979) Raphe unit activity in freely moving cats: correlation with level of behavioral arousal. Brain Res 163:135-50.

Wafford KA, Ebert B (2008) Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time. Nature Rev Drug Discov. doi:10.1038/nrd2464.

Wang QP, Nakai Y (1994) The dorsal raphe: an important nucleus in pain modulation. Brain Res Bull 34:575-585.

Wetter TC, Lauer CJ, Gillich G, et al (1996) The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs. J Psychiat Res 30:411-419.

Winokur A, Kamath J (2008) The effect of typical and atypical antipsychotic drugs on sleep of schizophrenic patients. In: Monti JM, Pandi-Perumal SR, Jacobs BL, et al, eds. Serotonin and Sleep: Molecular, Functional and Clinics Studies. Basel: Birkhäuser, pp. 587-610

Yamashita H, Morinobu S, Yamakawi S, et al (2002) Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol. Psychiatry Res 109:137-142.

Zhang C, Marek GJ (2008) AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated prefrontal cortical excitatory synaptic currents and DOI-induced head shakes. Prog Neuropsychopharmacol Biol Psychiatry 32:62-71.

Defeat Drugs and Live Free

Defeat Drugs and Live Free

Being addicted to drugs is a complicated matter condition that's been specified as a disorder that evidences in the obsessional thinking about and utilization of drugs. It's a matter that might continue to get worse and become disastrous and deadly if left untreated.

Get My Free Ebook


Post a comment